<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193671</url>
  </required_header>
  <id_info>
    <org_study_id>Ksundfeldt</org_study_id>
    <nct_id>NCT03193671</nct_id>
  </id_info>
  <brief_title>Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis</brief_title>
  <official_title>Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the biomarkers CA125 and HE4 and the algorithms RMI and ROMA on a normal
      population in the western region of Sweden. The aim is to improve diagnosis of ovarian
      cancer.

      If the investigators observe a clear improvement in the early diagnosis of EOC, the
      investigators aim to implement the best strategy for all patients with suspected pelvic tumor
      mass in the western region of Sweden.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are currently using CA125 and RMI in diagnosing patients with a pelvic
      cyst/tumor and referring them to tertiary centers for surgery in the western region of
      Sweden. The diagnostic accuracy is unsatisfying why the investigators are evaluating HE4 and
      ROMA as a complement, in combination or separately to improve diagnostic accuracy.

      The trial is based on a normal population cohort of patients included at all the hospitals in
      the region. The patients were included before surgery and the biomarkers analysed on serum
      samples withdrawn preoperatively.

      If the investigators observe a clear improvement in the early diagnosis of EOC, the
      investigators aim to implement the best strategy for all patients with suspected pelvic tumor
      mass in the western region of Sweden.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 29, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Can the investigators improve diagnostic accuracy in women diagnosed with a cyst/tumor in the pelvis</measure>
    <time_frame>12 months</time_frame>
    <description>Finding the true cases and avoiding unnecessary surgery, a descriptive analysis of a normalpopulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improve triage of patients to tertiary centers for surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Referring the correct cases from a normal population.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">684</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Diagnoses Disease</condition>
  <condition>Biomarkers</condition>
  <condition>Algorithms</condition>
  <arm_group>
    <arm_group_label>Benign</arm_group_label>
    <description>Benign tumors, pre-and postmenopausal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant</arm_group_label>
    <description>Malignant tumors, pre-and postmenopausal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Borderline</arm_group_label>
    <description>Borderline tumors, pre-and postmenopausal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant+borderline</arm_group_label>
    <description>Malignant+borderline tumors, pre-and postmenopausal</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnosis</intervention_name>
    <description>Improving diagnosis</description>
    <arm_group_label>Benign</arm_group_label>
    <arm_group_label>Malignant</arm_group_label>
    <arm_group_label>Borderline</arm_group_label>
    <arm_group_label>Malignant+borderline</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with a cyst/tumor in the pelvis already enrolled for surgery. Included
        at 6 different Hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age, understand spoken and written Swedish information, admitted for
             surgery for a cyst/tumos in the pelvis

        Exclusion Criteria:

          -  Rejected participation, cytotoxic chemotherapy prior to surgery, rejected surgery,
             serum sample failure, already included at another hospital
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Based on gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gothenburg University, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Göteborg University</investigator_affiliation>
    <investigator_full_name>Karin Sundfeldt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HE4</keyword>
  <keyword>CA125</keyword>
  <keyword>RMI</keyword>
  <keyword>ROMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All IPD are coded with a unique number only available to the main researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

